Therapy of Acute Leukaemia: Comparison of Initial Treatment with 6-Mercaptopurine Alone and in Combination with Steroids by Bridges, J. M. et al.
46
THERAPY OF ACUTE LEUKAEMIA:
COMPARISON OF INITIAL TREATMENT WITH 6-MERCAPTOPURINE
ALONE AND IN COMBINATION WITH STEROIDS
J. M. BRIDGES, D. M. HAYES AND M. G. NELSON
From The Department of Clinical Pathology, Royal Victoria Hospital, Belfast
Received for publication November 28, 1961
No re'gime of therapv which will cure acute leukaemia is yet available. The
use of blood transfusions, antibiotics, steroid hormones, the purine or folic acid
antagonists will, in some cases, cause temporary improvement. A few patients
treated by these agents may be restored for short periods to almost normal
health. These measures, however, have been aptly described by Dameshek
(1957) as of only
" pathetic benefit
" and he further states that should any
really good agents become available, the present re'gimes would be rapidly dis-
carded. Until such an event occurs, it is pertinent to examine the therapies at
present available and attempt to assess the optimum way in which they can be
used.
The difficulties in attempting to assess the relative merits of the various
therapeutic re'gimes, as reported from different centres, have been repeatedly
emphasised (Wintrobe, 1957 Hayhoe, 1960. In reported series, the selection
of patients, the morphological types of disease, the efficiency of what Farber
(1957) refers to as
" total care
" and the criteria for expression of results, all
combine to make direct comparisons largely invalid. If different re'gimes of
therapy are used in the same centre, and the results compared, then many of the
factors referred to above are cancelled out and a more accurate assessment
becomes possible.
Classification o Patients and Criteria ofRe8pon8e
The present paper deals with our experience in the management of fiftv adult
patients with acute leukaemia. An attempt is made to assess the value of initial
therapy in this disease with 6-Mercaptopurine alone and in combination with
steroids. All patients in this series survived diagnosis and the initiation of
therapy by a minimum of one week. Their ages varied from 15 to 77 years, and
males and females were equally distributed throughout the various age groups.
Morphological classification was based on the appearances of Leishmann stained
smears of peripheral blood and bone marrow; in many cases additional staining
techniques (e.g. Feulgen's method) were used, but like Hayhoe and Whitby
(1935) we found these methods added little of value.
Our cases were classified as-monoblastic 21, myeloblastic 10, lymphoblastic
10, and in 9 cases it was considered that the cells showed no differentiation and
these were designated as stem cell or blast cell leukaemia.
In assessing the results of therapy in our patients we have classified the
response into three grades-complete, partial or no response. A complete remis-THERAPY OF ACUTE LEUKAEMIA 47
sion was scored when a patient was able to resume his former level ofactivity and
in whom the peripheral blood picture, including haemoglobin level and platelet
count returned to within normal limits, and a bone marrow sample contained
not more than 10 per cent of blast cells. Patients were classified as making no
response if there was no evidence of clinical or haematological improvement, as
judged by haemoglobin concentration, platelet count and the failure of the
circulating primitive cells to diminish by at least 50 per cent. Partial response is
thus by definition, all responses which fall between these two groups.
All patients in the present series were given blood transfusions and antibiotics
as indicated. It has been claimed by Dreyfus (1948), Bessis and Dausset (1950),
and Hayboe and Whitby (1955) that remissions may be induced in a significant
number of adult patients with acute leukaemia by the use of blood transfusions
alone. We, however, have not attempted to allow for benefit following non-
specific tberapy, and in assessing our results have assumed that the benefits of
such therapy, if any, were equal in both main groups.
Therapeutic Regimes
The 50 patients in the present series fall into two distinct groups-(a) those
given 6-Mercaptopurine alone, and (b) those given steroids in combination with
6-Mereaptopurine.
6-Mercaptopurine
The drug 6-Mercaptopurine, which blocks the metabolism of purine by in-
hibiting the formation of nucleic acid, was first subjected to clinical trial by
Burchenal, Murpby, Ellison, Sykes, Tan, Leon, Karnofsky, Craver, Dargeon and
Rboads (1953) and by Hall, Richards, Willet and Feichtmeir (1954). These
studies suggested that the drug was of value in the treatment of chronic granulo-
cytic and acute leukaemia but not in other malignant diseases ; these findings have since been confirmed by many authors.
The dose schedule which we employed was 2-5 mg. per kilo body weight daily
to a total dose of 6-8 g. over a period of 4-6 weeks. Evidence of a haematologica-I
response usually appeared aftertherapy had beengiven for 2 weeks, the maximum
benefit being evident after 4 weeks. It was found that the degree of clinical
improvement paralleled thehaematological remission.
In all our cases the action ofthe drug was confined to the haemopoietic system. In the patients who responded leucopaenia occurred which was mainly due to
elimination of the primitive cells from the peripheral blood. In no case was it
considered that thromboyetopaenia or anaemia was caused solely by a toxic
action of the drug on either megakaryocytes or red cell precursors. Fourteen cases have been treated with 6-Mercaptopurine alone (Table 1);
9 did not respond to treatment. Two had partial remissions which lasted 4 and
6 months respectively, but when subsequent relapse occurred, they proved re-
fractory to further therapy. The 3 complete remissions lasted one month in one
ca,se and 6 months in the other 2 cases. When these cases relapsed after their
initial satisfactory response, it was possible to induce further partial remissions
of short duration in 2, who were of the non-monoblastic type. All patients treated with 6-Mereaptopurine alone are dead. The average
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TABLE I.-Response to 6-Mercaptopurine
Cornplete Partial
Type Nurnber rernission remission No response
Monoblastic 7 1 1 5
Lymphoblastic 2 1 0 1
Myeloblastic 3 1 0 2
Blastic 2 0 1 1
Total 14 3 2 9
for those who made no response it was 1-5 months; for those with a partial
response it was 6-5 months; and for those with an initial complete remission,
survival after diagnosis was 11 months. The immediate cause of death in these
patients is set out in Table IL
TABLE II.-Immediate Causes of Death in Patients with Acute Leukaemia
Steroids and
6-Mercaptopurine 6-Mereaptopurine
Generalised haemorrhages 6 14
Cerebral haemorrhage alone 7
Cachexia 7 7
Septicaemia 7
Liver failure I
Pulmonary embolus
The reports of the efficiency of 6-Mercaptopurine in adult acute leukaemia
have varied widely. Hall et al. (1954), Fountain (1955), and Whitelaw, Moffat,
Perry and Beck (1956) reported favourable responses in some 50 per cent of their
patients. Bross (1954), however, analysed the data from twenty-three centres
where this drug had been used, and found that, excluding patients with mono-
blastic leukaemia, only one adult in 7 had made a favourable response. Many
authors have noted that the monoblastic type of the disease was more refractory
to therapy than the other morphological types, but in this present small series this
difference was not apparent.
Steroids and 6-Mercaptopurine
One of the earliest reports on the use of steroid hormones in acute leukaemia
was by Pearson, Eliel, Talbot, Burchenal, Petro, Poppell and Craver (1950).
These drugs are unique amongst those used for the treatment of this disease in
that they are closely related to naturally occurring metabolic products. Their
use in this field was stimulated by the observation of Dougherty and White
(1943), that administration of ACTH to rats caused atrophy oflymphoid tissue.
The dose of these drugs has varied widely and, with the introduction of the
newer analogues, relatively larger doses can now be used with less risk of side
effects. The initial daily dose which we have employed has been 60-100 mg.
prednisone or its equivalent dose of cortisone acetate or methyl-prednisolone,
which was maintained for 14 days. If no response was obtained, the dose was
reduced slightly to the order of 40-60 mg. prednisone and continued at this level
for a further 2 weeks before it was gradually withdrawn. If response was evident
after 2 weeks' therapy the daily dosage was reduced and the drug gradually
withdrawn over a further period of 3 to 4 weeks. In a few patients who initiallyTHERAPY OF ACUTE LEUKAEMIA 49
responded, a, reduction of the daily dose of steroid resulted in frank clinical and
haematological relapse. In these patients the minimum dose of steroid necessary
to maintain symptomatic relief was given and no attempt was made to further
reduce the dose unless serious side effects developed. The dose schedule of
6-Mercaptopurine when used in combination with steroids was the same as when
it was the only drug given.
We have now treated 36 patients with 6-Mercaptopurine and steroids; 12
achieved complete remission, 11 partial remission, whilst in 13 no worthwhile
response was obtained. When steroids were combined with 6-Mercaptopurine
thepattern ofresponse was somewhat different to that seen with 6-Mercaptopurine
alone. Clinical improvement appeared earlier, usually between 5 and 10 days
after the start oftherapy and tended to precede haematological change.
The 12 patients who had complete remissions following the first course of
treatment are now dead. These initial remissions lasted from 2 to 23 months
with an average duration of 6-3 months. Subsequentrelapses proved resistant to
therapy in 7 cases ; in 4 cases further partial remissions were obtained, but only
in one patient was a further complete remission obtained. This was a case of
lymphoblastic leukaemia whose initial remission lasted 23 months, and who had a
second complete remission lasting 4 months following the reintroduction of
therapy. Subsequent relapse was drug refractory and she eventually died of
septicaemia 29 months after diagnosis.
In all the II patients who achieved initial partial remissions, these lasted
from one to 10 months with an average duration of 3-8 months. All thesepatients
are now dead and in all but 3 subsequent relapse proved resistant to therapy.
In 2 of these a further partial remission lasted 2 and 4 months respectively.
The third patient, a male aged 54 years, is of special interest as he survived the
diagnosis by 33 months yet at no time was his peripheral blood free ofprimitive
cells.
The 13 patients who showed no significant clinical or haematological response
survived diagnosis by periods varying from 2 weeks to 5 months. It is our
impression that many of these patients, though not improved clinically in that
their symptoms were not relieved, were able to face the discomforts of the disease
with more equanimity.
All of the 36 patients given combined therapy are dead and haemorrhage was
the cause ofdeath in 21 ofthesepatients. Fourteen ofthem had a severe haemor-
rhagic diathesis with bleeding into the skin and from mucosal surfaces, and in
many the terminal event was cerebral haemorrhage. The remaining 7 patients
also died of cerebral haemorrhage but showed no other clinical signs of a haemor-
rhagic diathesis. Furthermore, death occurred whilst on therapy and was un-
expected in that, at the relevant time, their general clinical condition was fair.
Of the remaining 15 non-survivors, 7 died in a cachectic state, 7 died from septi-
caemia and in one the terminal event was liver failure.
Side, effects of steroids
In a disease such as acute leukaemia, which runs a variable course and pro- duces a wide variety ofsymptoms and signs, it is very difficult to estimate accur-
ately the toxic effects of any drug being given. All patients on steroids were
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tested for sugar, and serum electrolytes estimated at frequent intervals. We
saw no evidence of fluid retention, electrolyte upset or hypertension. Seven
patients developed glycosuria, the onset of which did not bear any relationship to
the dose given. The glycosuria was always mild and blood sugars during this
period never exceeded 240 mg. per 100 ml. In all cases the glycosuria rapidly
disappeared when the dose of steroids was reduced. The most definite steroid
side effect which we encountered was the development of Cushingoid features.
Many patients developed mild mooning of the face, but in only 3 was this severe,
being associated with cutaneous striae and
" buffalo hump ". The dose of
steroid which these patients had received variedgreatly; in 2 cases, over aperiod
of 4 to 6 months, 3-0-3-5 g. of prednisone or its equivalent were given, whereas
in one patient these side effect became evident after an initial course of 4 weeks,
during which time 1-5 g. ofprednisone had been given.
Seven ofthe 36 patients given steroids developed septicaemia. This condition
ran a fulminant course in spite of supportive therapy with cortisone acetate and
multiple antibiotics. In all cases the septicaemia proved fatal.
Two patients developed severe gastro-intestinal haemorrhage whilst on
steroids ; both were in the terminal stages ofthe disease and had a severe haemor-
rhagic diathesis including bleeding from other mucosal surfaces. Peptic ulcera-
tion is a well-recognised complication of steroid therapy but no proven example
occurred in the present series.
Of 36 patients given steroids, 20 were given prednisone, 13 methhyl-predni-
solone and 3 cortisone acetate. The side effects described above cannot be
correlated in incidence and severity with the steroid preparation used. Myo-
pathy, however, was encountered in 2 patients both of whom were treated with
methyl-prednisolone ; they received total doses of 6 g. and 1-6 g. over a period
of I I and 4 months respectively. This complication produced a somewhat
similar clinical picture and both patients complained of difficulty in climbing
stairs, and evidence ofmuscle weaknessaffecting almostexclusively the quadriceps
muscle groups was noted. This condition improved, but only slowly, after
reduction of methvl-presnisolone.
Respon8e by Type and Age
Tables I and III show the response of the various morphological types of the
TABLE III.-Respon8e to 6-Mercaptopurine and Steroids
Complete Partial No
Type Total remission remission remission
Monoblastic 14 2 4 8
Lymphoblastic 8 5 I 2
Myeloblastic 7 2 3 2
Blastic 7 3 3 I
Total 36 12 11 13
disease to therapy. In patients given 6-Mercaptopurine alone, no correlation was
noted between response and the type of leukaemia, but amongst those given
6-Mercaptopurine and steroids, patients with monoblastic leukaemia showed a
lower incidence of response than those with the other morphological ty-pes. It
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ineffective in patients with monoblastic leukaemia, but may cause acceleration of
the disease process. We encountered only one such patient in whom it was felt
that the steroids may have had a deleterious effect. This patient, a female
aged 30 years, had a white cell count of5,200 per cu.mm. at the onset oftherapy,
but after 5 days pf prednisone, this started to rise rapidly and within 10 days
had risen to 52,000 per cu.mm. Thisrising white cell count was accompanied by
arapid deterioration in the chnical condition. A similar phenomenon was noted,
however, in a patient with lymphoblastic leukaemia. In general, our results in
patients with monoblastic leukaemia treated by steroids and 6-Mereaptopurine
are similar to those obtained with 6-Mercaptopurine alone. In monoblastic
leukaemia we feel that steroids areworthy oftrial should resistance to 6-Mereapto-
purine be encountered.
TABLE IV.-Response by Age and Morphological Type
Age groups (years)
-A,
r
15-29 30-49 50+ Total
Monoblastic . Number of cases 5 5 11 21
Number of responses 2 2 4 8
Lymphoblastic Number of cases 6 3 1 10
Number of responses 5 2 0 7
Myeloblastic Number of cases 4 2 4 10
Number of responses 3 2 1 6
Blastic Number of cases 6 1 2 9
Number of responses 5 1 1 7
Total Cases 21 11 18 50
Responses 15 7 6 28
In Table IV the response to therapy is correlated with the age of the patient
and type of the disease. Our two therapeutic groups, taken as a whole, were
fairlycomparable asregards agedistribution, butamongst thosegiven 6-Mercapto-
purine alone there was a slightly higher proportion of patients with the mono-
blastic variety of the disease. In general, and irrespective of age, patients with
monoblastic leukaemia responded poorly. If one excludes patients with this
type, there would appear to be a difference in response dependent on age. Thus
of 16 patients under the age of 30 years with non-monoblastic leukaemia, 13
made a response to therapy, whereas of 13 over the age of 30 years only 7 res-
sponded. Gunz and Hough (1956) have found that elderly patients with acute
leukaemia are very refractory to therapy, and our findings would also support the view that with increasing age the chance of a worthwhile response to chemo-
tberapy is lessened.
Response by Initial White Cell Count
In Table V the response to treatment is correlated with the level of the wliite
cefl count at diagnosis. In the present series of 50 patients, 31 had a white cell
count of under 20,000 per cu.mm. at the time ofdiagnosis, in 10 the initial white
ceR count lay between 20,000-40,000 per cu.mm. and in the remaining 9 it ex-
ceeded 40,000 per cu.mm. The two therapeutic groups contained comparable52 J. M. BRIDGES, D. M. HAYES AND M. G. NELSON
TABLEV.-Respon-se to Therapy Related to Initial White Cell Count
Tnitial white cell count/c.mm.
Type 0-20,000 20-40,000 40,000+
Monoblastic Number of'cases 14 6 1
Nuinber of responses 5 3 0
Lympboblastic Number of cases 6 0 4
Nurnber of responses 5 0 0
Myeloblastic Number of cases 5 2 3
Nuriiber of responses 4 1 1
Blastic Number of cases 6 2 1
Nuinber of responses 6 0 1
Total (lases 31 10 9
Responses 20 4 4
numbei-s of patients presenting with low, moderate and high white cell counts.
Of the 31 patients whose initial white cell count was under 20,000 per cu.mm.,
20 m,,,tde a favourable response to therapy; of the 19 whose initial count was
greater than 20,000 per cu.mm. 8 responses. The impression that an initial
white cell count of under 20,000 per cu.mm. carried a more favourable prognosis
is enhanced if one excludes those patients with the monoblastic variety of the
disease. Of 17 such patients with initial leucocyte counts of under 20,000 15
made a favourable response to therapy, whereas of 12 with initial counts greater
than 20,000 per cu.mm. only 5 made a favourable response. That patients with
acute leukaemia in whom the initial leucocyte count is high have a poorer prog-
nosis than those in whom it is within normal limits, has been the experience of
other workers (Zuelzer, 1949 ; Koler, Seaman and Osgood, 1956). Haut, Altman,
Wintrobe and Cartwright (1959), however, found that this occurred only in their
patients with the lymphoblastic variety of leukaemia and not in patients with
myeloblastic disease. Whether the slight benefit enjoyed by those with initial
low leucocyte counts reflects a grepter response to therapy or is indicative of a
less fulminant disease process is not clear.
DISCITSSION
It is now generally agreed that 6-Mercaptopurine and steroids are the drugs
ofmost value in the manactement of acute leukaemia in the adult but the optimum
wav in which these agents should be used is as yet not clearly established. The
present work attempts to assess the efficiency of initial therapy with 6-Mercapto-
purine alone as compared with 6-Mercaptopurine and steroids combined. These
regimes may be judged by comparing the relative numbers of patients achieving
some worth while response and the average survival of patients treated by each
method. One difference between the two re'gimes which we have noted and
which does not become apparent from studying the data we have presented, is
the pattern of response. In patients given 6-Mereaptopurine, the response
occurred only after some 2 to 3 weeks therapy, whereas amongst those given com-
bined therapy the large majority of responses were evident within 10 days. This
difference in the pattern of response which has previously been noted (Hayhoe,
1960) would suggest that steroids may act not only as a cytotoxic agent but also53 THERAPY OF ACUTE LEUKAEMIA
may have a direct stimulatory effect on surviving normal marrow elements
(Dameshek and Gunz, 1958).
Before one can compare results of therapy in two groups of patients with
acute leukc-,emia, one must ensure that the two groups are comparable. This
means that each must containpatients ofthe same ages, have anequal distribution
ofthe various types ofleukaernia and have the same number ofpatientspresenting
with low and high initial leucocyte counts. It is essential that all these factors
be considered as, irrespective of treatment, they all affect prognosis. Thus our
group given 6-Mercaptopurine alone contained a relatively higher proportion of
patients with the monoblastic variety of acute leukaemia and this must be
allowed for in evaluating the results oftherapy.
The average survival (from diagnosis until death) of the 14 patients given
6-Mercaptopurine alone was 4-3 months ; the 7 patients with the monoblastic
variety survived an average period of 2-1 months and the remainder survived
6-5 months. The average survival of 36 patients given initial therapy with
6-Mercaptopurine combined with steroids was 6-4 months ; the 14 patients with
monoble,stic leukaemia so treated, survived 2-7 months and the 22 patients with
the other varieties of the disease survived diagnosis by an average period of 8-8
months. Thus, consideration of average survival times shows that in patients
with monoblastic leukaemia, no improvement is obtained by the addition of
steroids to initial therapy with 6-Mercaptopurine. However, our patients with
the
" non-monoblastic
" variety of leukaemia treated by 6-Mercaptopurine com-
bined with steroids survived onthe average somewhat longer thanthosetreatedby
6-Mercaptopurine alone.
Consideration of the relative numbers of patients obtaining a significant
response also suggests that initial combined therapy in patients with non-mono-
blastic leukaemia is of more value than 6-Mercaptopurine alone. Thus, of 14
patients given 6-Mercaptopurine, 5 achieved a significant response ; of 7 with
monoblastic leukaemia 2 responsed, and of 7 with the other types of leukaemia
3 responded. Of our 36 patients given combined therapy 23 responded; of
14 with monoblastic leukaemia 6 achieved a useftil remission, whereas of 22 with
non-monoblastic leukaemia 17 responded.
Whilst our series is far too small to allow valid statistical conclusions, we feel
that consideration of number of responses and average survival times tends to
confirm our clinical impression that by the use of initial therapy with 6-Mercapto-
purine and steroids it is possible to achieve somewhat better results than if
6-Mercaptopurine is used alone.
However, even ifthe above conclusions areregarded as valid before advocating combined therapy as the re'gime of choice, one must consider the side effects of
therapy. Tt is in this connection that the difference between the groups is most
marked. In our hands, 6-Mercaptopurine has been singularly free of toxic effects
and in no patient was any interference with any bodily system other than the
haemopoietic system noted. In complete contrast to this, our patients given
steroids suffered many and diverse side effects. Those directly attributable to
the steroid therapy were Cushingoid facies, glycosuria and myopathy. Mild
mooning ofthe face occurred in manv of our patients but inonly 3 did theCushing- oid features become so marked as to cause the patient discomfort and embarrass-
ment. One of these patients had had only a few weeks' course of steroid therapy
when the Chashingoid features became evident. Despite withdrawal of the drug54 J. M. BRIDGES, D. M. HAYES AND M. G. NELSON
these did not appreciably regress throughout the remaining 6 months of her life.
Myopathy, which was seen in only 2 patients both given methyl-prednisolone,
regressed when the dosage of steroids was reduced, as did the glycosuria seen in
7 patients.
Apart from these definite side effects other more subtle complications, some
of which are difficult to separate from those of the leukaemic process, were noted.
The most important of these is the alteration of the patient's ability to resist
infection induced by steroid therapy. It is recognised that py-rexial episodes are
frequent in leukaemia and, if careful studies are made, infective agents either
bacterial, viral or fungal, can be shown to be the cause of the majority of these
(Louis, Limarzi and Lepper, 1956; Silver, Utz, Freia and McCullough, 1958).
Our data on the incidence of infectioil is incomplete, as all py-rexial episodes were
not thoroughly investigated. It is, however, our strong impressure that oral
moniliasis was more troublesome in patients on steroid therapy. A study of
the causes of death (Table 11) shows that septicaemia occurred more frequently
in patients on steroids. It was noteworthy that all such septicaemic patients
also showed clinical evidence of adrenal failure. This caused considerable diffi-
culty in management, so that, in spite of intensive supportive and antibiotic
therapy, the septicaemia ran a fulminant and rapidly fatal course. The most
frequent infecting organism was found to be a penicillin-resistant staphviococcus.
It is highly probable that the infecting organism was acquired from the hospital
environment. It is important, therefore, during hospitalization that every
effort should be made to isolate patients with acute leukaemia and nurse them
appropriatelv.
A most aisappointing feature about our steroid treated group was the high
incidence of haemorrhage as a terminal event. This was somewhat unex'Pected
as in acute leukaemia one of the main indications for these drugs is the presence
of a haemorrhagic diathesis, where it is hoped that such therapy will reduce the
incidence ofbleeding as well as controlling the leukaemic process. Amongst our
21 patients treated by steroids who died as a direct result of uncontrollable
haemorrhage, there were 7 who showed a somewhat unusual clinical picture.
This occurred whilst they were on moderate to high doses of steroids and at a
time when no other clinical evidence of a haemorrhagic diathesis was present.
A similar mode of termination was not noted in any of ourpatients who had Tiot
received steroids. As it had been shown that prolonged steroid therapy in
children may cause a rise in intracranial pressure (Benson and Pharoah, 1960),
it is tempting to postulate that the high dose of steroids which our patients
received may, in some way, have predisposed them to the development of cerebral
haemorrhage.
In the light of our experience as reported here, we feel that in patients with
monoblastic leukaemia, the addition of steroids to 6-Mereaptopurine as initial
therapy is of little value. We also feel that in patients with the
" non-mono-
blastic
" varieties of the disease, initial combined therapy possesses slight but
definite advantages in the prolongation of life and in significantly influencing the
disease in a larger number of patients. But this is achieved only at the expense
ofmany serious side effects. Our studies lead us to believe that 6-Mereaptopurine,
as initialtherapy, is the treatment of choice for all types ofadult acute leukaemia.
We recognise steroids to be of undoubted value in management of this disease,
but consider that they should be added only when the patient's condition mayTHERAPY OF ACUTE LEUKAEMIA 55
make an immediate response imperative or when resistance to 6-Mereaptopurine
is encountered.
ST-TMMARY
Fifty cases of acute leukaemia in adults are reviewed.
Fourteen patients were given 6-Mercaptopurine as initial therapy and in 36
steroids were combined with this drug.
Evidence ispresented that inpatients with the
" non-monoblastic
" varieties of
the disease initialtherapy with steroids and6-Mereaptopurine is somewhatsuperior
to 6-Mercaptopurine alone.
The incidence of side effects in patients given steroids was considerable.
This included Cushingoid facies, glycosuria, myopathy and septicaemia.
It is suggested that 6-Mercaptopurine is the initial treatment of choice for
adult acute leukaemia and steroids should be reserved for the acutely ill patient
and for those resistant to the action of 6-Mercaptopurine.
One of us (J. M. B.) is pleased to acknowledge a whole-time grant from the
British Empire Cancer Campaign.
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